Citigroup Inc Neurocrine Biosciences Inc Transaction History
Citigroup Inc
- $163 Billion
- Q4 2024
A detailed history of Citigroup Inc transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Citigroup Inc holds 165,180 shares of NBIX stock, worth $18.3 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
165,180
Previous 200,519
17.62%
Holding current value
$18.3 Million
Previous $23.1 Million
2.33%
% of portfolio
0.01%
Previous 0.01%
Shares
14 transactions
Others Institutions Holding NBIX
# of Institutions
656Shares Held
96.6MCall Options Held
282KPut Options Held
281K-
Black Rock Inc. New York, NY14.2MShares$1.57 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$1.12 Billion0.02% of portfolio
-
State Street Corp Boston, MA4.89MShares$542 Million0.03% of portfolio
-
Dodge & Cox San Francisco, CA3.02MShares$334 Million0.26% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.54MShares$281 Million0.06% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $10.6B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...